Review of precision cancer medicine: Evolution of the treatment paradigm. [PDF]
, 2020 In recent years, biotechnological breakthroughs have led to identification of complex and unique biologic features associated with carcinogenesis. Tumor and cell-free DNA profiling, immune markers, and proteomic and RNA analyses are used to identify ...
Fountzilas, Elena +3 more
core +1 more source
NTRK Somatic Fusions and Tumor Agnostic Treatment in Pediatric Cancers
Journal of Contemporary Medicine, 2022 Neurotrophic tyrosine receptor kinase (NTRK) gene rearrangements have been recently identified and developed as one of the biomarkers that have been utilized as new targets for cancer therapy.
Emel Ünal +2 more
doaj +1 more source
Human Pathology Reports, 2022 Reliable neurotrophin kinase (NTRK) fusion assessment is of special relevance since durable responses to targeted therapies have been observed regardless tumor type, NTRK gene or fusion partner.
Almudena Santón +7 more
doaj +1 more source
A systematic comparison of pan-Trk immunohistochemistry assays among multiple cancer types [PDF]
, 2023 AIMS NTRK rearranged tumours are rare but can be successfully treated using anti-TRK-targeted therapies, making NTRK testing important for treatment choices in patients with advanced cancers.
Haberecker, Martina +4 more
core +1 more source
EML4–NTRK3 Fusion Cervical Sarcoma: A Case Report and Literature Review
Frontiers in Medicine, 2022 The concept of neurotrophic factor tyrosine kinase receptor (NTRK) fusion tumor has emerged in recent years. Moreover, NTRK fusion is unusual in common tumors but can often be identified in rare tumors.
Xiaohe Dang +4 more
doaj +1 more source
Generating in vitro models of NTRK-fusion mesenchymal neoplasia as tools for investigating kinase oncogenic activation and response to targeted therapy. [PDF]
Oncogenesis, 2023 The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions as pan-tumor oncogenic drivers has led to new personalized therapies in oncology.
Vanoli F +11 more
europepmc +2 more sources
Potential novel therapy targets in neuroendocrine carcinomas of the breast [PDF]
, 2018 Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several new targeted therapies based on specific
Contreras, Elma +7 more
core +2 more sources
Frontiers in Oncology, 2023 NTRK fusions are validated oncogenic drivers of various adult and pediatric tumor types, including thyroid cancer, and serve as a therapeutic target. Recently, tropomyosin receptor kinase (TRK) inhibitors, such as entrectinib and larotrectinib, display ...
Qing-Xiang Yu +6 more
doaj +1 more source
Real-world challenges in undertaking NTRK fusion testing in non-small cell lung cancer. [PDF]
J Thorac Dis, 2023 Background We performed a retrospective analysis to determine the incidence of neurotrophic tropomyosin-receptor kinase (NTRK) fusion in non-small cell lung cancer (NSCLC).
Poh A +6 more
europepmc +2 more sources
Case Report: A case of complete response to entrectinib in NTRK fusion gene-positive parotid gland cancer. [PDF]
Front Oncol, 2023 Introduction Expression of the NTRK gene is rare in solid tumors but is highly prevalent in salivary gland secretory carcinomas. Here, we report a case of a complete response to entrectinib in a patient with NTRK fusion gene-positive parotid carcinoma ...
Moriyama E +10 more
europepmc +2 more sources